| Source: |
| Type: |
| PFS (progression-free survival) is the time from a defined starting point—usually randomization or treatment initiation—until documented disease progression or death, whichever occurs first |
| 9134- | CC, | Camu camu plus nivolumab/ipilimumab (N/I) as first-line therapy for metastatic renal cell carcinoma (mRCC): A randomized phase I trial |
| - | Trial, | RCC, | NA |
| 7482- | H2, | Molecular Hydrogen Therapy: Mechanisms, Delivery Methods, Preventive, and Therapeutic Application |
| - | Review, | Var, | NA | - | Review, | IBD, | NA | - | Review, | Stroke, | NA | - | Review, | Sepsis, | NA | - | Review, | AD, | NA |
| 7990- | itraC, | A Novel Approach to Reducing Chemoresistance in Advanced Ovarian Cancer: The Effect of Itraconazole-A Single-Institution Randomized Placebo-Controlled Trial |
| - | Trial, | Ovarian, | NA |
| 8018- | itraC, | Chemo, | Impact of combination chemotherapy with itraconazole on survival of patients with refractory ovarian cancer |
| - | Trial, | Ovarian, | NA |
| 8128- | LF, | Phase 2 trial of talactoferrin in previously treated patients with metastatic renal cell carcinoma |
| - | Trial, | RCC, | NA |
| - | Trial, | NSCLC, | NA |
| 8631- | MBZ, | BEV, | Mebendazole; from an anti-parasitic drug to a promising candidate for drug repurposing in colorectal cancer |
| - | Trial, | CRC, | NA |
| 8795- | mCHEMO, | Short-term versus long-term metronomic adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma: A propensity score-matched real-world study |
| - | Trial, | NPC, | NA |
| 8786- | mCHEMO, | Metronomic chemotherapy in cancer treatment: new wine in an old bottle |
| - | Review, | Var, | NA |
| 8792- | mCHEMO, | Early capecitabine metronomic chemotherapy improves patient prognosis and safety in early-stage triple-negative breast cancer |
| - | Trial, | BC, | NA |
| 7708- | NIV, | lpi, | Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial |
| - | Trial, | CRC, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:0 prod#:% Target#:1559 State#:% Dir#:2
wNotes=0 sortOrder:rid,rpid